Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 6, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,250,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 6, 2012.
- Price Range: Highest price paid was 1,401.5 pence per share; lowest price paid was 1,380.0 pence per share.
- Treasury Holdings (Settled): 520,790,427 shares (9.56% of total issued share capital).
- Treasury Holdings (Including Unsettled): 525,440,427 shares (10.67% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,924,639,378 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,250,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior level to 10.67% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the 1,250,000 share repurchase based on the weighted average price between 1,380.0 and 1,401.5 pence.
- Confirm the impact of the 10.67% Treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.